Aligos Therapeutics

Contributing Author

Recent Articles by Aligos Therapeutics

Oct-17	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ALGS GlobeNewswire
Oct-16	Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184 ALGS GlobeNewswire
Oct-14	Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference ALGS GlobeNewswire
Oct-07	Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting 2025 ALGS GlobeNewswire
Sep-03	Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting ALGS GlobeNewswire
Sep-02	Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference ALGS GlobeNewswire
Aug-20	Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramon Polo as Senior Vice President, Head of Global Regulatory Affairs ALGS GlobeNewswire
Aug-15	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ALGS GlobeNewswire
Aug-13	Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection ALGS GlobeNewswire
Aug-06	Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results ALGS GlobeNewswire
Jul-30	Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025 ALGS GlobeNewswire
Jul-11	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ALGS GlobeNewswire
Jun-18	Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC) ALGS GlobeNewswire
Jun-13	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ALGS GlobeNewswire
May-29	Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference ALGS GlobeNewswire
May-20	Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal ALGS GlobeNewswire
May-16	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ALGS GlobeNewswire
May-08	Aligos Therapeutics Presents Positive Data at the EASL Congress 2025 ALGS GlobeNewswire
May-06	Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results ALGS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.